Vitamin D for the management of multiple sclerosis

Jagannath, Vanitha A; Filippini, Graziella; Pietrantonj, Carlo Di; Asokan, G V; Robak, Edward W; Whamond, Liz; Robinson, Sarah

doi:10.1002/14651858.cd008422.pub3

Cited by 97 publications

(92 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, 11 records were included in this review [100,[204][205][206][207][208][209][210][211][212][213] (Supplemental Figure S6). We focused on publications that examined the association between vitamin D and the development of MS or clinical activity of MS. Supplemental Tables S22-S24 provide information about the included studies and the assessed quality based on AMSTAR 2.…”

Section: Resultsmentioning

confidence: 99%

“…Regarding clinical outcomes, eight publications that conducted SRs of mainly RCTs [204,205,207,[209][210][211][212][213] focused on changes in the expanded disability status scale (EDSS). In summary, the studies found no significant therapeutic effect of vitamin D on EDSS and/or concluded that vitamin D supplementation had no effects on EDSS.…”

Section: Therapeutic or Adjuvant Vitamin D Supplementation In Ms Patimentioning

confidence: 99%

See 1 more Smart Citation

Role of Vitamin D in Preventing and Treating Selected Extraskeletal Diseases—An Umbrella Review

Maretzke¹,

Bechthold²,

Egert

et al. 2020

Nutrients

View full text Add to dashboard Cite

Evidence is accumulating that vitamin D may have beneficial effects on respiratory tract, autoimmune, neuro-degenerative, and mental diseases. The present umbrella review of systematic reviews (SRs) of cohort studies and randomised controlled trials (RCTs), plus single Mendelian randomisation studies aims to update current knowledge on the potential role of vitamin D in preventing and treating these extraskeletal diseases. Altogether, 73 SRs were identified. Observational data on primary prevention suggest an inverse association between vitamin D status and the risk of acute respiratory tract infections (ARI), dementia and cognitive decline, and depression, whereas studies regarding asthma, multiple sclerosis (MS), and type 1 diabetes mellitus (T1DM) are scarce. SRs of RCTs support observational data only for the risk of ARI. No respective RCTs are available for the prevention of chronic obstructive pulmonary disease (COPD), MS, and T1DM. SRs of RCTs indicate beneficial therapeutic effects in vitamin D-deficient patients with asthma and COPD, while effects on major depression and T1DM need to be further elucidated. Mendelian randomisation studies do not consistently support the results of SRs. Since several limitations of the included SRs and existing RCTs do not permit definitive conclusions regarding vitamin D and the selected diseases, further high-quality RCTs are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Therapeutic or Adjuvant Vitamin D Supplementation In Ms Patimentioning

confidence: 99%

Role of Vitamin D in Preventing and Treating Selected Extraskeletal Diseases—An Umbrella Review

Maretzke¹,

Bechthold²,

Egert

et al. 2020

Nutrients

View full text Add to dashboard Cite

show abstract

“…The prioritisation criteria included the expected interest to people affected by MS and how current the review was. Unfortunately, the Cochrane Reviews on topics of broad interest such as exercise, diet, and vitamin D supplementation were not, at that time, sufficiently up to date to be included. The final reviews selected for the website were on immunotherapies for different types of MS, hyperbaric oxygen therapy, and rehabilitation …”

Section: Resultsmentioning

confidence: 99%

Producing an evidence‐based treatment information website in partnership with people affected by multiple sclerosis

Synnot

Hawkins

Merner

et al. 2018

Health Science Reports

Self Cite

View full text Add to dashboard Cite

Background and AimsIn earlier work, we identified that people affected by multiple sclerosis (MS) can have difficulty finding online treatment information that is up to date, trustworthy, understandable, and applicable to personal circumstances, but does not provoke confusion or negative emotional consequences. The objective was to develop online consumer summaries of MS treatment evidence (derived from Cochrane Reviews) that respond to identified treatment information needs of people affected by MS.MethodsA 2‐phase mixed‐methods project, conducted in partnership with consumers and an MS organisation. Phase 1 included review panels with consumers (Australians affected by MS) and health professionals to test paper‐based treatment summaries before development, and pilot testing of the website. Phase 2 involved an online survey after website launch.ResultsEighty‐three participants (85% affected by MS) took part. Phase 1 participants strongly endorsed key review summary components, including layering information, and additional sections to aid personal applicability. Participants additionally suggested questions for health professionals. Participants across both phases were receptive to the idea of being provided with Cochrane Review summaries online but were seeking other types of evidence and information, such as personal experiences and the latest experimental treatments, which could not be provided. While the small survey sample size (n = 58) limits application of the results to a broader population, the website was viewed favourably, as a useful, understandable, and trustworthy information source.ConclusionWe describe a partnership approach to developing online evidence‐based treatment information, underpinned by an in‐depth understanding of consumers' information needs.

show abstract

“…There is evidence that vitamin D deficiency is associated with increased risk of developing multiple sclerosis (MS) and with an increased rate of disease progression 1,2 . However, the therapeutic efficacy of vitamin D supplementation in MS patients is still an open question, and interventional trials have reported inconclusive results 3 .…”

Section: Introductionmentioning

confidence: 99%

“…It has been suggested that vitamin D2 supplementation reduces circulating vitamin D3 levels; however, a recent randomized controlled trial showed that the reciprocal is also true 11 . The general consensus is that vitamin D3 is the preferred form to be administered 3 , but few studies have compared D2 and D3 in terms of their direct cellular effects under controlled conditions. The mechanisms mediating the protective action of vitamin D in MS are not fully characterized.…”

Section: Introductionmentioning

confidence: 99%

Vitamins D3 and D2 have marked but different global effects on gene expression in a rat oligodendrocyte precursor cell line

Mengozzi

Hesketh

Bucca

et al. 2019

Preprint

View full text Add to dashboard Cite

AbstractVitamin D deficiency increases the risk of developing multiple sclerosis (MS) but there is uncertainty about what dose and form of vitamin D could improve the clinical course of MS. The mechanisms underlying the effects of vitamin D in MS are not clear. Vitamin D3 increases the rate of differentiation of primary oligodendrocyte precursor cells (OPCs), suggesting that it might help remyelination in addition to modulating the immune response. Here we analyzed the transcriptome of differentiating rat CG4 OPCs treated with vitamin D2 or with D3 at 24 h and 72 h following onset of differentiation. Differentiation alone changed the expression of about 10% of the genes at 72 h compared to 24 h. Vitamin D2 and D3 exerted different effects on gene expression, with D3 influencing 1,272 genes and D2 574 at 24 h. The expression of the vast majority of these genes was either not changed in differentiating cells not exposed to vitamin D or followed the same trajectory as the latter. D3-repressed genes were enriched for gene ontology categories including transcription factors and the Notch pathway, while D3-induced genes were enriched for the Ras pathway. These findings should help to identify mechanisms mediating D3 action in MS.

show abstract

Vitamin D for the management of multiple sclerosis

Abstract: Editorial group: Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group. Publication status and date: New search for studies and content updated (conclusions changed), comment added to review, published in Issue 9, 2018.

Cited by 97 publications

References 77 publications

Role of Vitamin D in Preventing and Treating Selected Extraskeletal Diseases—An Umbrella Review

Role of Vitamin D in Preventing and Treating Selected Extraskeletal Diseases—An Umbrella Review

Producing an evidence‐based treatment information website in partnership with people affected by multiple sclerosis

Vitamins D3 and D2 have marked but different global effects on gene expression in a rat oligodendrocyte precursor cell line

Contact Info

Product

Resources

About